Trial registrationĬ identifier NCT00805337 ConclusionĬancer-related frequencies appear to be tumor-specific and treatment with tumor-specific frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1 months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months (leiomyosarcoma metastatic to liver). One patient with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5 months. One patient with hormone-refractory breast cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. Thirteen patients were evaluable for response. There were no NCI grade 2, 3 or 4 toxicities. Three patients experienced grade 1 fatigue during or immediately after treatment. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Most frequencies (57–92%) were specific for a single tumor type. We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524 frequencies ranging from 0.1 Hz to 114 kHz. We offered compassionate treatment to some patients with advanced cancer and limited therapeutic options. We examined patients with various types of cancer using a noninvasive biofeedback method to identify tumor-specific frequencies. We undertook this study to identify tumor-specific frequencies and test the feasibility of administering such frequencies to patients with advanced cancer.
Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have a therapeutic effect.
0 kommentar(er)
